SEC Form 4 · accession 0001104659-26-107915
AgomAb Therapeutics NV · AGMB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Naimish Patel
Director
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002020932
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2,F3 | $13.94 | Sep 11, 2026 | A | 56,328 | A | — | Jan 15, 2036 | Common shares | 56,328 | 56,328 | D |
Explanation of responses
- F1The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
- F2The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.
- F333% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.